Facts that Destroy Shorts

2021-12-22

$Cassava Sciences Inc(SAVA)$ Facts that Destroy Shorts:1. SavaDx being used as an unvalidated biomarker diagnostic in CMS and Phase 3 trials.2. Yale replicating binding of simufilam to FLNA by screening other molecules for FLNA binding affinity.3. Yale showing FLNA conformational activity in a publication supporting Sava’s altered FLNA observation.4. Yale showing correlation of FLNA in AD in mouse model.5. Phase 3 currently recruiting and dosing.6. Using the Shorts theoretical DPM equation using the correct 0.1 mg of protein instead of the incorrect 0.1 ug used by shorts (consistent with other Sava assays) giving the correct theoretical 47,000 DPMs and confirming femtomolar binding of simufilam to FLNA…thank you shorts 😂.7. Safety and clinical efficacy data from many stakeholders and chain of custody shown for 12 month data.8. Two separate Journals stating no data manipulation

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":691154596,"tweetId":"691154596","gmtCreate":1640154178331,"gmtModify":1640154358428,"author":{"id":3479274696871559,"idStr":"3479274696871559","authorId":3479274696871559,"authorIdStr":"3479274696871559","name":"qwertd","avatar":"https://static.tigerbbs.com/c919127bf800db36898f470027bd6e99","vip":8,"userType":8,"introduction":"运营账号","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":85,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"Facts that Destroy Shorts","extraTitle":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> Facts that Destroy Shorts:1. SavaDx being used as an unvalidated biomarker diagnostic in CMS and Phase 3 trials.2. Yale replicating binding of simufilam to FLNA by screening other molecules for FLNA binding affinity.3. Yale showing FLNA conformational activity in a publication supporting Sava’s altered FLNA observation.4. Yale showing correlation of FLNA in AD in mouse model.5. Phase 3 currently recruiting and dosing.6. Using the Shorts theoretical DPM equation using the correct 0.1 mg of protein instead of the incorrect 0.1 ug used by shorts (consistent with other Sava assays) giving the correct theoretical 47,000 DPMs and confirming femtomolar binding of simufilam to FLNA…thank you shorts 😂.7. Safety and clinical efficacy data from many stakeholders and chain of custody shown for 12 month data.8. Two separate Journals stating no data manipulation</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> Facts that Destroy Shorts:1. SavaDx being used as an unvalidated biomarker diagnostic in CMS and Phase 3 trials.2. Yale replicating binding of simufilam to FLNA by screening other molecules for FLNA binding affinity.3. Yale showing FLNA conformational activity in a publication supporting Sava’s altered FLNA observation.4. Yale showing correlation of FLNA in AD in mouse model.5. Phase 3 currently recruiting and dosing.6. Using the Shorts theoretical DPM equation using the correct 0.1 mg of protein instead of the incorrect 0.1 ug used by shorts (consistent with other Sava assays) giving the correct theoretical 47,000 DPMs and confirming femtomolar binding of simufilam to FLNA…thank you shorts 😂.7. Safety and clinical efficacy data from many stakeholders and chain of custody shown for 12 month data.8. Two separate Journals stating no data manipulation</p></body></html>","text":"$Cassava Sciences Inc(SAVA)$ Facts that Destroy Shorts:1. SavaDx being used as an unvalidated biomarker diagnostic in CMS and Phase 3 trials.2. Yale replicating binding of simufilam to FLNA by screening other molecules for FLNA binding affinity.3. Yale showing FLNA conformational activity in a publication supporting Sava’s altered FLNA observation.4. Yale showing correlation of FLNA in AD in mouse model.5. Phase 3 currently recruiting and dosing.6. Using the Shorts theoretical DPM equation using the correct 0.1 mg of protein instead of the incorrect 0.1 ug used by shorts (consistent with other Sava assays) giving the correct theoretical 47,000 DPMs and confirming femtomolar binding of simufilam to FLNA…thank you shorts 😂.7. Safety and clinical efficacy data from many stakeholders and chain of custody shown for 12 month data.8. Two separate Journals stating no data manipulation","highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691154596","repostId":0,"isVote":1,"tweetType":1,"viewCount":1926,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["SAVA"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":758,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/691154596"}